Evidence map›Paper›PMID 42084708›Full record

ReviewInfectious diseases and therapy2026

Adult RSV Vaccination: What Is the Role of RSV Subgroup in Disease Prevention?

S Elizabeth Williams, Giovanni Checcucci Lisi, Kate Luisi, Kumar Ilangovan, Cassandra Hall-Murray, Kyla Hayford, Elizabeth Begier

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Infectious diseases and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

S Elizabeth WilliamsPfizer Vaccines, Pfizer, Inc., New York, NY, USA. elizabeth.williams@pfizer.com.ORCID http://orcid.org/0000-0001-5867-8162
Giovanni Checcucci LisiPfizer Vaccines, Pfizer, Inc., Rome, Italy.
Kate LuisiPfizer Vaccines, Pfizer, Inc., New York, NY, USA.
Kumar IlangovanPfizer Vaccines, Pfizer, Inc., New York, NY, USA.
Cassandra Hall-MurrayPfizer Vaccines, Pfizer, Inc., New York, NY, USA.
Kyla HayfordPfizer Vaccines, Pfizer, Inc., New York, NY, USA.
Elizabeth BegierPfizer Vaccines, Pfizer, Inc., Dublin, Ireland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Respiratory syncytial virus (RSV) cocirculates as two antigenic subgroups, RSV A and RSV B, with irregular dominance by season. Despite highly conserved fusion (F) protein epitopes, sequence, and antigenic differences between A and B, especially within prefusion F, can modulate neutralization and susceptibility. First-in-class adult RSV vaccines licensed in 2023 adopt two antigen strategies: monovalent stabilized prefusion F based on sequences from the RSV A subgroup, and bivalent stabilized prefusion F antigens from both RSV A and RSV B subgroups to decrease reliance on RSV A cross-protection. Clinical data from bivalent vaccine studies support high efficacy against disease from both subgroups, while monovalent vaccine studies suggest that RSV B cross-protection may wane more quickly. Emerging and continued real-world vaccine effectiveness monitoring of both monovalent and bivalent RSV vaccines will be needed to assess this early signal.

Indexed as

Antigenic subgroupCross-protectionRespiratory syncytial virusRSVVaccine

Identifiers

PMID42084708
PMCPMC13219652

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.